Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.

Pérez-Jiménez E, Kochan G, Gherardi MM, Esteban M.

Microbes Infect. 2006 Mar;8(3):810-22. Epub 2006 Jan 13.

PMID:
16504562
3.

High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Sorzano CO, Esteban M.

PLoS One. 2012;7(6):e38859. doi: 10.1371/journal.pone.0038859. Epub 2012 Jun 8.

4.

Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.

Fernández L, Carrillo E, Sánchez-Sampedro L, Sánchez C, Ibarra-Meneses AV, Jimenez MA, Almeida VDA, Esteban M, Moreno J.

Front Immunol. 2018 Apr 23;9:843. doi: 10.3389/fimmu.2018.00843. eCollection 2018.

5.
6.

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).

Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1204. doi: 10.1371/journal.pntd.0001204. Epub 2011 Jun 14.

7.

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.

Dondji B, Pérez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D.

Infect Immun. 2005 Aug;73(8):5286-9.

8.

Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Pérez-Jiménez E, Oliveros JC, Esteban M.

J Virol. 2013 Jun;87(12):6955-74. doi: 10.1128/JVI.03013-12. Epub 2013 Apr 17.

9.
10.

NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis.

Sánchez-Sampedro L, Mejías-Pérez E, S Sorzano CÓ, Nájera JL, Esteban M.

Virus Res. 2016 Jul 15;220:1-11. doi: 10.1016/j.virusres.2016.03.007. Epub 2016 Mar 29.

PMID:
27036935
11.

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.

Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.

J Exp Med. 1997 Oct 6;186(7):1137-47.

12.

The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.

Méndez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YA, Campos-Neto A, Reed S, Seder RA, Sacks D.

J Immunol. 2001 Apr 15;166(8):5122-8.

13.

A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.

Carson C, Antoniou M, Ruiz-Argüello MB, Alcami A, Christodoulou V, Messaritakis I, Blackwell JM, Courtenay O.

Vaccine. 2009 Feb 11;27(7):1080-6. doi: 10.1016/j.vaccine.2008.11.094. Epub 2008 Dec 16.

14.
15.
16.

Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, Miyake S, Yamamura T, McMahon-Pratt D.

Eur J Immunol. 2008 Mar;38(3):706-19. doi: 10.1002/eji.200737660.

17.
18.

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.

Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.

Exp Parasitol. 2011 Mar;127(3):627-36. doi: 10.1016/j.exppara.2010.12.007. Epub 2010 Dec 25.

PMID:
21187087
19.

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL.

Clin Vaccine Immunol. 2010 May;17(5):793-801. doi: 10.1128/CVI.00006-10. Epub 2010 Mar 31.

Supplemental Content

Support Center